search button

Paclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data

  • Authors:
    • Jun Li
    • Wan‑Li Liu
    • Xin Yi
    • Gao‑Ke Feng
    • Zhao Lu
    • Xue‑Jun Jiang
    • Xiao‑Yan Li

  • View Affiliations

  • Published online on: April 20, 2015     https://doi.org/10.3892/etm.2015.2431
  • Pages: 2285-2292
Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Paclitaxel-coated balloons (PCBs) have become attractive alternative treatment options for patients with in‑stent restenosis (ISR); however, the safety and efficacy of PCBs in comparison with those of conventional therapies are less well defined. The aim of this meta‑analysis was to systematically review the efficacy and safety of PCBs for patients with ISR using comparisons with control groups. Electronic databases, such as MEDLINE, Embase and the Cochrane Central Register of Controlled Trials, were searched, and eligible studies that compared PCBs with uncoated balloons (UCBs) or drug‑eluting stents (DESs) in patients with ISR were considered. Subgroup analyses were performed with different control groups. Nine studies (1,488 patients, 1,608 lesions) were included in the meta‑analysis. Compared with patients who underwent UCB angioplasty, those who underwent PCB angioplasty exhibited a clear superiority in late lumen loss (LLL) [weighted mean difference (WMD), ‑0.46; 95% confidence interval (CI), (‑0.59)‑(‑0.34); P<0.00001] and major adverse cardiac events (MACEs) [odds ratio (OR), 0.21; 95% CI, 0.13‑0.33; P<0.00001]. The OR for myocardial infarction (MI) (OR, 0.46; 95% CI, 0.15‑1.47; P=0.19) did not reach statistical significance. PCBs were associated with similar outcomes when compared with DESs with regard to LLL (WMD, ‑0.04; 95% CI, ‑0.18‑0.10; P=0.57), MACEs (OR, 0.74; 95% CI, 0.36‑1.53; P=0.42) and the ORs for all endpoints, including total mortality, target lesion revascularization, MI, stent thrombosis and binary restenosis, and no statistically significant differences were found. This meta‑analysis showed that PCBs are associated with superior outcomes when compared with UCBs in the management of ISR, and are at least as efficacious and as well tolerated as DESs.
View Figures
View References

Related Articles

Journal Cover

June-2015
Volume 9 Issue 6

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

  • Journal Metrics
  • Impact Factor: 2.4
  • Ranked Medicine Research and Experimental
    (total number of cites)
International Symposium on Molecular Medicine Conference Banner
The Cancer Story
World Congress on Advances in Oncology and International Symposium on Molecular Medicine Conference Banner
World Academy Of Sciences Banner
Heyday Road Banner

0

Copy and paste a formatted citation
x
Spandidos Publications style
Li J, Liu WL, Yi X, Feng GK, Lu Z, Jiang XJ and Li XY: Paclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data. Exp Ther Med 9: 2285-2292, 2015.
APA
Li, J., Liu, W., Yi, X., Feng, G., Lu, Z., Jiang, X., & Li, X. (2015). Paclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data. Experimental and Therapeutic Medicine, 9, 2285-2292. https://doi.org/10.3892/etm.2015.2431
MLA
Li, J., Liu, W., Yi, X., Feng, G., Lu, Z., Jiang, X., Li, X."Paclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data". Experimental and Therapeutic Medicine 9.6 (2015): 2285-2292.
Chicago
Li, J., Liu, W., Yi, X., Feng, G., Lu, Z., Jiang, X., Li, X."Paclitaxel-coated balloons for the treatment of patients with in-stent restenosis: A meta-analysis of angiographic and clinical data". Experimental and Therapeutic Medicine 9, no. 6 (2015): 2285-2292. https://doi.org/10.3892/etm.2015.2431